LIF As We Know It: From Basic Science to Clinical Trials

Barcelona, Spain : 28 - 29 May 2018

Scientific Programme

Monday 28th May 2018

12:30

Registration

Foyer of VHIO

13:00

WELCOME LUNCH

14:00

Conference Introduction

Cellex Auditorium

Session 1 - LIF in cancer I

Chair: Joan Seoane

14:10

Joan Seoane VHIO, Spain

"Immunomodulatory role of LIF in cancer"

14:50

Cédric Gaggioli IRCAN, France

"A journey into the tumor microenvironment: a LIF(e) story"

15:30

Wenwei Hu Rutgers Cancer Institute, USA

"LIF, a Friend or Foe – its role in reproduction and cancer"

16:10

COFFEE BREAK

Session 2 - Early phase clinical trials

Chair: Joan Seoane

16:45

José Baselga MSKCC, USA

"Update on clinical development of anti-LIF antibodies as cancer therapy"

17:25

Lillian Siu University of Toronto, Canada

"Incorporating predictive biomarker development in first-in-class phase I trials – myth or must?"

18:05

Josep Tabernero VHIO, Spain

"New development strategies in Immuno-Oncology"

18:45

Bus to Evening Reception

19:00

Evening Reception

Hotel Alimara

All participants are invited to join this networking event. Drinks and hors d'oeuvres will be served in the garden of the hotel. The event will finish at 20:30, and the rest of the evening is free for you to enjoy Barcelona.

Tuesday 29th May 2018

Session 3 - LIF in cancer II

Chair: Tony Hunter

09:00

Tony Hunter Salk Institute, USA

"LIF produced by stromal cells is a paracrine factor acting on tumor cells in pancreatic cancer"

09:40

Benjamin Neel NYU School of Medicine, USA

"Targeting SHP2 in cancer"

10:20

Peter Heinrich Albert-Ludwig University, Germany

"IL-6 type cytokines: signaling through the gp130-JAK-STAT pathway and its regulation"

11:00

COFFEE BREAK

11:30

Andrew Lowy UCSD, USA

"Identifying novel targets for pancreatic cancer therapy"

12:10

Manuel Serrano IRB Barcelona, Spain

"Critical role of the LIF-family of cytokines during the early phases of reprogramming into pluripotency"

12:50

LUNCH

Session 4 - LIF in inflammation

Chair: Su Metcalfe

13:50

Su Metcalfe University of Cambridge, UK

"NanoBioMedicine: Nano-formulation of LIF to treat Multiple Sclerosis, an inflammatory autoimmune disease of the CNS"

14:30

Niels Hellings Hasselt University, Belgium

"IL-6 class cytokines are master regulators of neuroimmunological disease"

15:10

Keith Pennypacker University of Kentucky, USA

"Age-related differences in the response to Leukemia Inhibitory Factor after experimental stroke"

15:50

General conclusions & Award presentation

Joan Seoane Scientific Organiser

16:15

COFFEE & FINAL NETWORKING

Until 17:00

X [close tab]